Antibiotic‐associated diarrhoea (AAD) is one of the most common side effects of antibiotic therapy. The main mechanism associated with the development of AAD is significant changes in the composition and quantity of the gut microbiota during the treatment with antibiotics. Probiotic bacteria have been shown to stabilize the gut microbiota and can be used to prevent diarrhoea associated with antibiotic therapy.
Case presentation:
We present the results of a single‐centre, randomized, double‐blinded, placebo‐controlled clinical trial. Patients were randomized into three groups: probiotic group 1 received a probiotic containing strains Bacillus subtilis 3 and Bacillus licheniformis 31; probiotic group 2 received a probiotic, containing B. subtilis 3; and the placebo group received an inert composition in vials, formulated to be indistinguishable from the vials with probiotics. Participants received one vial twice a day. Probiotic treatment significantly reduced incidents of AAD in the patients. Among 91 patients in group 1 treated with probiotic mix, nine developed AAD. In group 2, seven patients out of 90 who received only one probiotic strain developed AAD. A considerably higher incidence of AAD was registered in the placebo group – 23 from 90 patients (P<0.001 vs groups 1 and 2). Both probiotics demonstrated a significant effect in the prevention of nausea, bloating, vomiting and abdominal pain.
Conclusion:
Treatment with Bacillus probiotics during antibiotic therapy significantly decreased the incidence of AAD and adverse effects related to the use of antibiotics. Both probiotics were well tolerated by the patients without side effects. No significant difference was found in the efficacy of the two probiotics.
CananiR.B.,
CirilloP.,
TerrinG.,
CesaranoL.,
SpagnuoloM.I.,
de VincenzoA.,
AlbanoF.,
PassarielloA.,
de MarcoG.other authors(2007). Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. Br Med J 335:340[CrossRef]
CoppiF.,
RuoppoloM.,
MandressiA.,
BellorofonteC.,
GonnellaG.,
TrinchieriA.(1985). Results of treatment with Bacillus subtilis spores (Enterogermina) after antibiotic therapy in 95 patients with infection calculosis. Chemioterapia 4:467–470
FriedmanG.(2012). The role of probiotics in the prevention and treatment of antibiotic‐associated diarrhea and Clostridium difficile colitis. Gastroenterol Clin North Am 41:763–779[CrossRef]
GaoX.W.,
MubasherM.,
FangC.Y.,
ReiferC.,
MillerL.E.(2010). Dose–response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic‐associated diarrhea and Clostridium difficile‐associated diarrhea prophylaxis in adult patients. Am J of Gastroenterol 105:1636–1641[CrossRef]
GorkiewiczG.(2009). Nosocomial and antibiotic‐associated diarrhoea caused by organisms other than Clostridium difficile
. Int J Antimicrob Agents 33:S37–S41[CrossRef]
GrachevaN.M.,
GavrilovA.F.,
Solov’evaA.I.,
SmirnovV.V.,
SorokulovaI.B.,
ReznikS.R.,
ChudnovskaiaN.V.(1996). The efficacy of the new bacterial preparation biosporin in treating acute intestinal infections. Zh Mikrobiol Epidemiol Immunobiol75–77
KalmanD.S.,
SchwartzH.I.,
AlvarezP.,
FeldmanS.,
PezzulloJ.C.,
KriegerD.R.(2009). A prospective, randomized, double‐blind, placebo‐controlled parallel‐group dual site trial to evaluate the effects of a Bacillus coagulans‐based product on functional intestinal gas symptoms. BMC Gastroenterol 9:85[CrossRef]
PersbornM.,
GerritsenJ.,
WallonC.,
CarlssonA.,
AkkermansL.M.A.,
SoderholmJ.D.(2013). The effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis. Aliment Pharmacol Ther 38:772–783[CrossRef]
PinchukI.V.,
BressollierP.,
VerneuilB.,
FenetB.,
SorokulovaI.B.,
MegraudF.,
UrdaciM.C.(2001).In vitro anti‐Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. Antimicrob Agents Chemother 45:3156–61[CrossRef]
SorokulovaI.(2008). Preclinical testing in the development of probiotics: a regulatory perspective with Bacillus strains as an example. Clin Infect Dis 46:S92–S95[CrossRef]
SorokulovaI.B.,
PinchukI.V.,
DenayrollesM.,
OsipovaI.G.,
HuangJ.M.,
CuttingS.M.,
UrdaciM.C.(2008). The safety of two Bacillus probiotic strains for human use. Dig Dis Sci 53:954–963[CrossRef]
YoungV.B.,
SchmidtT.M.(2004). Antibiotic‐associated diarrhea accompanied by large‐scale alterations in the composition of the fecal microbiota. J Clin Microbiol 42:1203–1206[CrossRef]